FDA postpones decision on weight-loss drug by 3 months

04/9/2012 | Reuters

The FDA told Vivus it won't rule on weight-loss pill Qnexa until July 17 because the agency needs extra time to look at the drugmaker's risk evaluation and mitigation strategy. In February, an advisory panel decided that Qnexa's benefits outweigh the risks.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC